Seattle Genetics signs $4.4bn worth oncology deals with Merck

Seattle Genetics signs $4.4bn worth oncology deals with Merck

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]

AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter’s DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), which is being developed for the treatment of multiple tumor types. Daiichi Sankyo is developing the antibody drug conjugate for multiple tumors […]

Olema Oncology raises $54m for breast cancer drug candidate OP-1250

Olema Oncology raises $54m for breast cancer drug candidate OP-1250

Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women’s cancers, has raised $54 million in a Series B financing round, which was co-led by BVF Partners, Logos Capital, and Janus Henderson Investors. The US biopharma company will use the proceeds for advancing OP-1250, its lead drug candidate in breast cancer, into […]

Genetron Health’s semiconductor-based NGS system gets Chinese approval

Genetron Health’s semiconductor-based NGS system gets Chinese approval

Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the approval, the Chinese precision oncology company can launch the new desktop medium-throughput NGS system for clinical applications. The NGS system has been developed by Genetron Health for the detection of […]

GE Healthcare unveils Serena Bright mammography solution for biopsy

GE Healthcare unveils Serena Bright mammography solution for biopsy

GE Healthcare has unveiled new Serena Bright, a contrast-enhanced mammography solution for biopsy, which is claimed to help clinicians to detect breast cancer patients in a better way. The company claimed that SenoBright HD contrast-enhanced spectral mammography is an imaging tool for diagnosis that has the potential to detect malignant lesions which cannot be seen […]

Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab emtansine) for post-surgery treatment of HER2-positive early breast cancer (EBC) in patients with residual invasive disease who were subjected to before surgery taxane and Herceptin (trastuzumab)-based treatment. The Kadcyla FDA […]

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]

GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline

GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline

GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This strategic acquisition, which was first announced in December 2018, is expected to significantly bolster GSK’s presence in the oncology sector, reinforcing its pharmaceutical business and enhancing its pipeline and commercial […]

Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials

Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials

Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in extending progression-free survival (PFS) for women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. This conclusion comes from a release of subgroup analyses from the […]